X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
striatum-enriched phosphodiesterase (52) 52
index medicus (36) 36
phosphoric diester hydrolases - metabolism (35) 35
animals (31) 31
pde10a (28) 28
immunohistochemical localization (27) 27
schizophrenia (27) 27
phosphodiesterase inhibitors - pharmacology (24) 24
humans (22) 22
pharmacology & pharmacy (19) 19
rats (19) 19
neurosciences (18) 18
phosphodiesterase inhibitors - chemistry (15) 15
male (14) 14
phosphoric diester hydrolases - chemistry (14) 14
basal ganglia (13) 13
chemistry, medicinal (13) 13
phosphodiesterase (13) 13
camp (12) 12
cyclic-nucleotide phosphodiesterases (12) 12
dopamine (12) 12
rats, sprague-dawley (12) 12
mice (11) 11
huntingtons-disease (10) 10
biochemistry & molecular biology (9) 9
inhibitors (9) 9
nucleotide phosphodiesterase (9) 9
phosphoric diester hydrolases - genetics (9) 9
antipsychotics (8) 8
cyclic amp - metabolism (8) 8
models, molecular (8) 8
phosphodiesterase 10a (8) 8
phosphodiesterase inhibitors - therapeutic use (8) 8
protein binding (8) 8
psychosis (8) 8
rat-brain (8) 8
structure-activity relationship (8) 8
subcellular-localization (8) 8
brain (7) 7
chemistry, organic (7) 7
dose-response relationship, drug (7) 7
10a inhibitors (6) 6
analysis (6) 6
brain - metabolism (6) 6
crystallography, x-ray (6) 6
discovery (6) 6
female (6) 6
localization (6) 6
papaverine - pharmacology (6) 6
pde10a inhibitors (6) 6
phosphodiesterase inhibitors - chemical synthesis (6) 6
schizophrenia - drug therapy (6) 6
signal transduction - drug effects (6) 6
article (5) 5
binding sites (5) 5
molecular structure (5) 5
motor activity - drug effects (5) 5
orally-active pyrazoloquinolines (5) 5
phosphodiesterase inhibitors - pharmacokinetics (5) 5
psychiatry (5) 5
rat (5) 5
rats, wistar (5) 5
antipsychotic agents - pharmacology (4) 4
antipsychotic agents - therapeutic use (4) 4
behavior, animal - drug effects (4) 4
brain - diagnostic imaging (4) 4
cgmp (4) 4
cognition (4) 4
cognitive ability (4) 4
corpus striatum - drug effects (4) 4
corpus striatum - enzymology (4) 4
cyclic gmp - metabolism (4) 4
drug discovery (4) 4
drug evaluation, preclinical (4) 4
drugs (4) 4
enzymes (4) 4
medium spiny neuron (4) 4
mental disorders (4) 4
molecular docking simulation (4) 4
nervous system diseases (4) 4
neurons - drug effects (4) 4
nucleus-accumbens (4) 4
papaverine (4) 4
phosphodiesterases (4) 4
phosphorylation (4) 4
prepulse inhibition (4) 4
pyrazoles - pharmacology (4) 4
quinolines - pharmacology (4) 4
reflex, startle - drug effects (4) 4
research (4) 4
striatum (4) 4
10a (3) 3
animal models (3) 3
antipsychotic (3) 3
antipsychotic agents - pharmacokinetics (3) 3
avoidance learning - drug effects (3) 3
brain - drug effects (3) 3
catalytic domain (3) 3
cns (3) 3
crystal-structure (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncogene, ISSN 0950-9232, 03/2015, Volume 34, Issue 12, pp. 1499 - 1509
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 11/2009, Volume 331, Issue 2, pp. 574 - 590
Journal Article
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 215 - 223
Phosphodiesterase 10A (PDE10A) is a novel target for the treatment of schizophrenia that may address multiple symptomatic domains associated with this... 
Schizophrenia | Phosphodiesterase 10A | Striatum | Cognition | OBJECT RETRIEVAL | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | IMMUNOHISTOCHEMICAL LOCALIZATION | STRIATUM-ENRICHED PHOSPHODIESTERASE | AMPA RECEPTOR | SYNAPTIC PLASTICITY | NEUROSCIENCES | PREFRONTAL CORTEX | MEMORY DYSFUNCTION | DOPAMINE-D-2 RECEPTOR OCCUPANCY | ANIMAL-MODELS | PHARMACOLOGY & PHARMACY | Pyrimidines - blood | Memory, Episodic | Male | Macaca mulatta | Cognition Disorders - prevention & control | Antipsychotic Agents - therapeutic use | Behavior, Animal - drug effects | Neurons - metabolism | Phosphorylation - drug effects | Pyridines - administration & dosage | Phosphodiesterase Inhibitors - pharmacokinetics | Rats | Random Allocation | Neurons - enzymology | Corpus Striatum - drug effects | Pyrimidines - pharmacokinetics | Phosphodiesterase Inhibitors - therapeutic use | Schizophrenia - metabolism | Rats, Wistar | Antipsychotic Agents - blood | Pyridines - pharmacokinetics | Molecular Targeted Therapy | Corpus Striatum - metabolism | Dose-Response Relationship, Drug | Protein Processing, Post-Translational - drug effects | Schizophrenia - physiopathology | Cognition Disorders - etiology | Neurons - drug effects | Corpus Striatum - enzymology | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Phosphoric Diester Hydrolases - metabolism | Schizophrenia - blood | Pyrimidines - administration & dosage | Nootropic Agents - pharmacokinetics | Nootropic Agents - therapeutic use | Antipsychotic Agents - pharmacokinetics | Nootropic Agents - blood | Phosphodiesterase Inhibitors - blood | Phosphoric Diester Hydrolases - chemistry | Antipsychotic Agents - administration & dosage | Nerve Tissue Proteins - metabolism | Phosphodiesterase Inhibitors - administration & dosage | Pyridines - blood | Animals | Nootropic Agents - administration & dosage | Pyrimidines - therapeutic use | Schizophrenia - drug therapy | Executive Function - drug effects | Enzymes | Plasma physics | Protein binding
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2007, Volume 104, Issue 14, pp. 5782 - 5787
Phosphodiesterases (PDEs) hydrolyze the second messengers cAMP and cGMP. It remains unknown how individual PDE families selectively recognize cAMP and cGMP.... 
Phosphates | Molecules | Hydrogen bonds | Active sites | Substrate specificity | Crystals | Atoms | Amino acids | Zinc | Crystal structure | Cyclic nucleotides cAMP and cGMP | INHIBITOR SELECTIVITY | MECHANISM | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | CRYSTAL-STRUCTURE | IMMUNOHISTOCHEMICAL LOCALIZATION | MULTIDISCIPLINARY SCIENCES | SUBCELLULAR-LOCALIZATION | CATALYTIC DOMAIN | cyclic nucleotides cAMP and cGMP | STRIATUM-ENRICHED PHOSPHODIESTERASE | PDE10A | crystal structure | DRUG DEVELOPMENT | Amino Acid Sequence | Catalytic Domain | Metals, Heavy - metabolism | Phosphoric Diester Hydrolases - metabolism | Models, Chemical | Humans | Glutamine - metabolism | Models, Molecular | Molecular Sequence Data | Substrate Specificity | Crystallography, X-Ray | Phosphoric Diester Hydrolases - genetics | Phosphoric Diester Hydrolases - chemistry | Sequence Homology, Amino Acid | Phosphoric Diester Hydrolases - isolation & purification | Cyclic GMP - metabolism | Hydrogen Bonding | Cations, Divalent - metabolism | Protein Conformation | Glutamine - chemistry | Kinetics | Mutation | Binding Sites | Cyclic AMP - metabolism | Cyclic adenylic acid | Research | Nucleotides | Phosphodiesterases | Structure | GLUTAMINE | SPECIFICITY | SUBSTRATES | CONFIGURATION | 08 HYDROGEN | CRYSTAL STRUCTURE | national synchrotron light source | MATERIALS SCIENCE | HYDROGEN | MUTANTS | ALIGNMENT | AMINO ACIDS | PHOSPHODIESTERASES | Biological Sciences
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 07/2010, Volume 30, Issue 27, pp. 9027 - 9037
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 02/2015, Volume 352, Issue 2, pp. 327 - 337
Journal Article
CNS DRUGS, ISSN 1172-7047, 2008, Volume 22, Issue 12, pp. 983 - 993
Recent studies have suggested that currently available antipsychotic medications, while useful in treating some aspects of schizophrenia, still possess... 
DIFFERENTIAL EXPRESSION | MICE DEFICIENT | PSYCHIATRY | INHIBITOR ROLIPRAM | STRIATUM-ENRICHED PHOSPHODIESTERASE | CLINICAL NEUROLOGY | CYCLIC-AMP PHOSPHODIESTERASE | CAMP-PHOSPHODIESTERASE | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | RAT-BRAIN | NUCLEOTIDE PHOSPHODIESTERASE | RADIAL-ARM MAZE
Journal Article
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 01/2011, Volume 17, Issue 2, pp. 137 - 150
Disturbances of the basal ganglia processes is heavily involved in schizophrenia. Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which... 
PDE10A structure | Phosphodiesterase 10A | Basal ganglia | Dopamine | Schizophrenia | Psychosis | cAMP/PKG | PDE10A | Pro-cognitive | cGMP/PKG | Antipsychotic | Striatopallidal | Striatonigral | Signalling cascades | IMMUNOHISTOCHEMICAL LOCALIZATION | CRYSTAL-STRUCTURE | signalling cascades | STRIATUM-ENRICHED PHOSPHODIESTERASE | schizophrenia | psychosis | 10A INHIBITORS | SUBSTRATE-SPECIFICITY | striatopallidal | pro-cognitive | IN-VIVO | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | antipsychotic | RAT-BRAIN | striatonigral | dopamine | Cyclic AMP-Dependent Protein Kinases - metabolism | Phosphodiesterase Inhibitors - therapeutic use | Schizophrenia - metabolism | Phosphoric Diester Hydrolases - metabolism | Humans | Basal Ganglia - metabolism | Phosphodiesterase Inhibitors - pharmacology | Rats | Clinical Trials as Topic | Phosphoric Diester Hydrolases - genetics | Molecular Targeted Therapy | Phosphoric Diester Hydrolases - chemistry | Receptors, Dopamine D1 - metabolism | Animals | Signal Transduction - drug effects | Mice | Phosphodiesterase Inhibitors - chemistry | Schizophrenia - drug therapy | Basal Ganglia - drug effects | Drugs | Potentiation | Protein kinase A | Emotional behavior | Animal models | Mental disorders | Cognitive ability | Clinical trials | Cyclic AMP | Data processing | Dopamine D1 receptors | Cyclic GMP | hydrolase | phosphodiesterase | Dopamine D2 receptors
Journal Article
Diabetes, ISSN 0012-1797, 01/2014, Volume 63, Issue 1, pp. 300 - 311
Journal Article